Status:
COMPLETED
Atazanavir/Ritonavir and Zinc Pharmacokinetic Study
Lead Sponsor:
St Stephens Aids Trust
Conditions:
HIV Infection
Eligibility:
All Genders
18-65 years
Phase:
PHASE4
Brief Summary
The study is being conducted as the most common side effect of the HIV drug atazanavir (taken with ritonavir) is hyperbilirubinaemia. Bilirubin is a normal waste product from the body and gets broken ...
Detailed Description
Atazanavir is a protease inhibitor (PI) and, like other agents in this class, requires pharmacological 'boosting' with the cytochrome p450 inhibitor ritonavir. Ritonavir slows the hepatic clearance of...
Eligibility Criteria
Inclusion
- The ability to understand and sign a written informed consent form, prior to participation in any screening procedure and must be willing to comply with all study requirements
- Male or non-pregnant, non-lactating females.
- Aged between 18 to 65 years, inclusive.
- Documented HIV-1 infection
- Plasma HIV RNA less than 40 copies/mL (note retesting of screening viral load is allowed).
- CD4 count \> 100 at screening (note retesting of screening CD4 count is allowed).
- Receiving an antiretroviral regimen of Truvada and atazanavir/ritonavir for more than 3 months.
- Serum total bilirubin concentration greater than 25 micromol/L
- Agrees not to change regimen, outside the study recommendations, from baseline until end of the treatment period unless this is medically indicated as decided by their treating physician.
Exclusion
- Any serious or active medical or psychiatric illness, which, in the opinion of the investigator, would interfere with subject treatment, assessment, or compliance with the protocol. This would include any active clinically significant renal, cardiac, hepatic, pulmonary, vascular, metabolic disorders or malignancy.
- Body mass index (BMI) \>35 kg/m2
- Presence of any current active AIDS defining illness (Category C conditions according to the CDC Classification System for HIV Infection 1993) with the following exceptions:
- • Stable cutaneous Kaposi's Sarcoma
- Clinically relevant alcohol or drug use (positive urine drug screen, with the exception of cannabinoids) or history of alcohol or drug use considered by the Investigator to be sufficient to hinder compliance with treatment, follow-up procedures or evaluation of adverse events.
- The use of zinc supplements for 1 month before screening and disallowed concomitant therapy (See Concomitant Medication and treatment, section 5.2) or medication that may interfere with the study results (as determined by the principal investigator).
- Females of childbearing potential who are not using effective non-hormonal birth control methods or not willing to continue using these birth control methods for at least 14 days after the end of the treatment period.
- Previous allergy to any of the constituents of the zinc sulphate tablets administered in this trial.
- Subjects with laboratory evidence of significantly decreased hepatic or renal function (as determined by the principal investigator).
- Exposure to any investigational drug or placebo within 4 weeks of first dose of study drug
Key Trial Info
Start Date :
December 1 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
March 1 2012
Estimated Enrollment :
16 Patients enrolled
Trial Details
Trial ID
NCT01475227
Start Date
December 1 2011
End Date
March 1 2012
Last Update
March 22 2012
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
St Stephen's AIDS Trust
London, United Kingdom, SW10 9NH